Enhancing mAb Platform Process using Membrane Affinity Chromatography for FIH Molecules
About this webinar
Membrane chromatography offers significant advantages over traditional column chromatography, including higher throughput, reduced processing times and enhanced scalability, making it an interesting tool in biologics production.
This study investigates the use of Protein A membrane chromatography for monoclonal antibody (mAb) purification in a contract research, development and manufacturing organization (CRDMO) setting involved in biologics development and manufacturing of first-in-human (FIH) molecules.
The expert speakers focus on the use of a mAb platform from resin-based to membrane Protein A chromatography, evaluating productivity, material cost and plant occupancy at 50, 500 and 2000 L scales. Results indicate this technology’s potential benefits for clinical development and improved operational flexibility.
Register for this webinar to understand how advanced technology can enhance throughput, reduce processing times and scales efficiently in a CRDMO setting for first-in-human molecule production.
Who should attend
- Bioprocess Development Scientist and Engineers
- CRDMO and Biologics Manufacturing Professionals
- Quality assurance/Regulatory affairs experts
- R&D and Process Development Teams
- Biotechnology and Pharmaceutical Executives
What you will learn
- How Protein A membrane chromatography enhances monoclonal antibody (mAb) purification, offering higher throughput and reduced processing times
- How this technology is implemented in a CRDMO setting for biologics development, particularly for FIH molecules
- The key differences in productivity, cost efficiency and plant occupancy across different scales (50 L, 500 L, and 2000 L)
- How this approach can optimize clinical development workflows and increase scalability for biologics manufacturing
Featured Speakers
Indraneel Sanyal
Indraneel Sanyal, Senior Director, Process Development, Aragen, has over three decades of experience. He specializes in developing robust, commercial-scale biologics processes and leading successful technology transfers. His expertise spans customized technical roadmaps from gene to clinic, early-phase accelerated development, risk assessment and mitigation strategies.
He has a strong background in clinical phase-specific project execution, process development and characterization, technology evaluation and transfer. Indraneel’s leadership has been instrumental in shaping innovative biotherapeutic development strategies.
Partner for this event
Aragen Life Sciences
Aragen Life Sciences is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. It offers end to end integrated and standalone solutions for small molecules and biologics from early discovery to commercial manufacturing. Established in 2001, the Company operates through a network of sites located globally with a team of 4500+ scientists and 450+ PhDs. Its expertise and experience have enabled over 400 customers to advance their research programs from discovery through commercialization. Aragen’s innovative mindset, infrastructure, flexible business models have enabled us to serve large pharma, biotech, agrochemical, animal health and performance chemical industries globally. Visit www.aragen.com for more details.
Related webinars
More from Aragen.
Crystallization Strategies for API Development and Scale-Up
Advanced In Vivo Efficacy Models for Preclinical Success
Advances in HPAPI Development and Regulatory Strategy
PROTACs: Breaking Boundaries in Drug Discovery
Process Development of New Chemical Entities — Overcoming Challenges of Safety and Quality for a Seamless Technology Transfer
Amorphous Solid Dispersion — An Ideal Formulation Approach to Improve Developability of Poorly Soluble Molecules
Accelerating Vaccines to Clinical Trials — A Toolkit for Efficacy, Safety and Bioanalytical Studies
Upstream Process Development for Better Yield and Product Quality
The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development
Driving Better Titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform
Brain Metastases – Challenges of Developing Clinically Relevant Preclinical Models
Development of Covalent Drugs with New Emerging Technologies